Today, LifeArc provides intellectual property identification, protection and commercialisation, technology development, diagnostic development, early stage drug discovery and antibody humanization services for academic, biotechnological and pharmaceutical organisations. Profits from LifeArc's activities are reinvested into further research.
History
The organisation was set up as a charity and a company limited by guarantee in 2000 to incorporate patenting, licensing and research functions.[3]
In 2010, LifeArc signed a deal with the drug company AstraZeneca to share chemical compounds to help identify potential treatments for serious diseases.[5][6]
LifeArc is a member of a Global Drug Discovery Alliance along with the Centre for Drug Research and Development, the Scripps Research Institute, Cancer Research Technology, the Lead Discovery Centre and the Centre for Drug Design and Discovery.[7] Through its earnings from licensing agreements, LifeArc provides funding for academic research and early-stage medical research.[8]
In March 2019, LifeArc joined with Cancer Research UK and Ono Pharma to progress new immunotherapy drug targets for cancer.[9]
In May 2019, LifeArc announced it had sold part of its royalty rights for Keytruda to a subsidiary of Canada Pension Plan Investment Board (CPPIB) for US$1.297 billion, making it one of the biggest UK medical charities by size of investment.[10]
The charity claims that it has found a new approach for treating Alzheimer's disease in research carried out with the Universities of Leicester and Göttingen.[11]
↑ Mark Wigglesworth, Terry Wood, eds, Management of Chemical and Biological Samples for Screening Applications, 2012, John Wiley & Sons, ISBN3527645276, 9783527645275, google books
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
